Trial · NCT01724021
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
NCT01724021, Phase 3, Completed, Hoffmann-La Roche; results first posted 2016-08-29
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a. Trials, record NCT01724021. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01724021
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
- NCT number
- NCT01724021
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 743 participants, actual
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
- Interventions
- Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP), Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP), Bendamustine, Rituximab, Rituximab, Rituximab, Rituximab
- First posted
- 2012-11-09
- Last updated
- 2018-01-23
- Other registries' IDs
- eudract:2012-003230-17
- Results first posted
- 2016-08-29
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 | Cycle 6 (Up to 24 weeks) | Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 6. |
| Primary | Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8 | Cycle 8 (Up to 32 weeks) | Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing Cycle 8. |
| Secondary | Number of Participants With Treatment Emergent Adverse Events (AEs) | Randomization of first participant to clinical cutoff date (Up to 4 years) | An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
| Secondary | Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV]) | Cycle 1-4, Cycle 5-8 for both SC and IV (Up to 32 weeks) | Administration time was defined as the time from start to end of the SC injection or from start to end of the IV infusion |
| Secondary | Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | During Cycle 4, 8 of treatment (Up to 32 weeks) | CTSQ is a validated 16-item questionnaire that measures three domains related to participants' satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. |
| Secondary | Rituximab Administration Satisfaction Questionnaire (RASQ) Score | During Cycle 4, 8 of treatment (Up to 32 weeks) | The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. |
| Secondary | Complete Response (CR) Rate | 28 days (± 3 days) after Day 1 of the last dose of induction treatment | CR rate was assessed according to the International Working Group (IWG) Response Criteria (CHESON ET AL. 1999) and included CR and CR unconfirmed (CRu). CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by \> 75 % but still \>1.5 cm in size, and indeterminate bone marrow assessment. Tumor assessments were based on computed tomography (CT) scans with contrast of the neck, chest, and abdomen (if detectable by these techniques) or other diagnostic means, if applicable. Other methods (e.g., MRI) were acceptable for participants in whom contrast CT scans were contraindicated. Due to the limited availability of FDG-PET scanners, an FDG-PET scan was not mandated in the study. |
| Secondary | Event-free Survival (EFS) | From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years) | EFS was defined as the time from randomization to first occurrence of progression or relapse according to IWG response criteria. IWG criteria is defined using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; partial response (PR): At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses; stable disease (SD): participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease (PD); PD: Lymph nodes considered abnormal if the long axis is more than 1.5 centimeter (cm) regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes less than or equal to (\<=) 1.0 × \<= 1.0 cm would not be considered as abnormal for PD. |
| Secondary | Disease-free Survival (DFS) | From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years) | DFS was defined as the period from the data of the initial CR/CRu until the date of relapse or death from any cause, whichever occurred first. |
| Secondary | Progression-free Survival (PFS) | From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years) | PFS was defined as the time from randomization to the first occurrence of progression or relapse, according to the IWG response criteria. IWG criteria is defined criteria using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; PR: At least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses; SD: participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for PD; PD: Lymph nodes considered abnormal if the long axis is more than 1.5 cm regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes \<= 1.0 × \<= 1.0 cm would not be considered as abnormal for PD. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 | Cycle 6 (Up to 24 weeks) | ITT population included all participants who were randomized in the study. Number of participants analyzed specifies number of participants who were evaluable for the outcome measure. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8 | Cycle 8 (Up to 32 weeks) | ITT population included all participants who were randomized in the study. Number of participants analyzed specifies number of participants who were evaluable for the outcome measure. | percentage of participants | NUMBER |
| SECONDARY | Number of Participants With Treatment Emergent Adverse Events (AEs) | Randomization of first participant to clinical cutoff date (Up to 4 years) | The safety population included all participants who received at least one dose of rituximab. Number of participants analyzed specifies number of participants who were evaluable for the outcome measure. | participants | NUMBER |
| SECONDARY | Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV]) | Cycle 1-4, Cycle 5-8 for both SC and IV (Up to 32 weeks) | ITT population included all participants who were randomized in the study. | minutes | MEDIAN |
| SECONDARY | Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | During Cycle 4, 8 of treatment (Up to 32 weeks) | ITT population included all participants who were randomized in the study. Here, Number Analyzed represents the number of participants who were evaluable at specified time points. | units on a scale | MEAN |
| SECONDARY | Rituximab Administration Satisfaction Questionnaire (RASQ) Score | During Cycle 4, 8 of treatment (Up to 32 weeks) | ITT population included all participants who were randomized in the study. Here, Number Analyzed represents the number of participants who were evaluable at specified time points. | units on a scale | MEAN |
| SECONDARY | Complete Response (CR) Rate | 28 days (± 3 days) after Day 1 of the last dose of induction treatment | ITT population included all participants who were randomized in the study. Number of participants analyzed specifies number of participants who were evaluable for the outcome measure. | percentage of participants | NUMBER |
| SECONDARY | Event-free Survival (EFS) | From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years) | ITT population included all participants who were randomized in the study. | months | MEDIAN |
| SECONDARY | Disease-free Survival (DFS) | From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years) | ITT population included all participants who were randomized in the study. | months | MEDIAN |
| SECONDARY | Progression-free Survival (PFS) | From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years) | ITT population included all participants who were randomized in the study. | months | MEDIAN |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 outcomesResults by group112
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 | Arm A | 79.1 | 95% Confidence Interval 74.2 to 83.5 | percentage of participants | |
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 | Arm B | 80.6 | 95% Confidence Interval 75.7 to 84.8 | percentage of participants | |
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8 | Arm A | 77.1 | 95% Confidence Interval 71.9 to 81.8 | percentage of participants | |
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8 | Arm B | 84.2 | 95% Confidence Interval 79.6 to 88.2 | percentage of participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) | Arm A | 352 | participants | ||
| Number of Participants With Treatment Emergent Adverse Events (AEs) | Arm B | 347 | participants | ||
| Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV]) | Rituximab Intravenous (IV) | 840 | Full Range 0 to 3967.0 | minutes | |
| Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV]) | Rituximab Subcutaneous (SC) | 22 | Full Range 0 to 1242.0 | minutes | |
| Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | Rituximab Intravenous (IV) | Expectations of therapy domain | 80.88 | Standard Deviation 18.315 | units on a scale |
| Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | Rituximab Subcutaneous (SC) | Expectations of therapy domain | 82.07 | Standard Deviation 17.817 | units on a scale |
1 to 10 of 112Source ClinicalTrials.gov
See all 112 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A | 371 | |
| Overall Study | STARTED | Arm B | 369 | |
| Overall Study | COMPLETED | Arm A | 244 | |
| Overall Study | COMPLETED | Arm B | 236 | |
| Overall Study | NOT COMPLETED | Arm A | 127 | |
| Overall Study | NOT COMPLETED | Arm B | 133 |
Source ClinicalTrials.gov
Adverse events364
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Arm A | 83 | 371 | |
| other | Nausea | Gastrointestinal disorders | Arm B | 102 | 369 | |
| other | Constipation | Gastrointestinal disorders | Arm A | 59 | 371 | |
| other | Constipation | Gastrointestinal disorders | Arm B | 60 | 369 | |
| other | Vomiting | Gastrointestinal disorders | Arm A | 44 | 371 | |
| other | Vomiting | Gastrointestinal disorders | Arm B | 57 | 369 | |
| other | Diarrhoea | Gastrointestinal disorders | Arm A | 45 | 371 | |
| other | Diarrhoea | Gastrointestinal disorders | Arm B | 50 | 369 | |
| other | Stomatitis | Gastrointestinal disorders | Arm A | 23 | 371 | |
| other | Stomatitis | Gastrointestinal disorders | Arm B | 23 | 369 |
1 to 10 of 364Source ClinicalTrials.gov
See all 364 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A | ||
| Total, all-cause mortality | Arm B | ||
| Total, other adverse events | Arm A | 318 | 371 |
| Total, other adverse events | Arm B | 317 | 369 |
| Total, serious adverse events | Arm A | 126 | 371 |
| Total, serious adverse events | Arm B | 116 | 369 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm A vs Arm B: Number of Participants With Treatment Emergent Adverse Events (AEs) | Trial comparisons |
| Arm A vs Arm B: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01724021
GET https://conductscience.org/api/trials/v1/NCT01724021/results?page=2